Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen

作者：Smith S D^*; Bolwell B J; Rybicki L A; Brown S; Dean R; Kalaycio M; Sobecks R; Andresen S; Hsi E D; Pohlman B; Sweetenham J W

来源：Bone Marrow Transplantation, 2007, 40(3): 239-243.

DOI：10.1038/sj.bmt.1705712

• autologous bone marrow transplant
• anaplastic large-cell lymphoma
• peripheral T-cell lymphoma

The role of high-dose therapy and autologous stem cell transplantation ( ASCT) for patients with peripheral T-cell lymphoma (PTCL) is poorly defined. Comparisons of outcomes between PTCL and B-cell non-Hodgkin's lymphoma (NHL) have yielded conflicting results, in part due to the rarity and heterogeneity of PTCL. Some retrospective studies have found comparable survival rates for patients with T- and B-cell NHL. In this study, we report our single-center experience of ASCT over one decade using a uniform chemotherapy-only high-dose regimen. Thirty-two patients with PTCL-unspecified (PTCL-u; 11 patients) and anaplastic large-cell lymphoma ( 21 patients) underwent autologous stem cell transplant, mostly for relapsed or refractory disease. The preparative regimen consisted of busulfan, etoposide and cyclophosphamide. Kaplan-Meier 5-year overall survival (OS) and relapse-free survival (RFS) a re 34 and 18%, respectively. These results suggest a poor outcome for patients with PTCL after ASCT, and new therapies for T- cell lymphoma are needed.

• 出版日期2007-8